Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.
Idris Nasir AbdullahiAnthony Uchenna EmeribeHafeez Aderinsayo AdekolaSharafudeen Dahiru AbubakarAmos DanganaHalima Ali ShuwaSunday Theophilus NwobaJelili Olaide MustaphaMuyideen Titilope HarunaKafayat Adepeju OlowookereOlawale Sunday AnimasaunCharles Egede UgwuSolomon Oloche OnojaAbdullahi Sani GadamaMusa MohammedIsa Muhammad DanejiDele Ohinoyi AmaduPeter Elisha GhambaNkechi Blessing OnukegbeMuhammad Sagir ShehuChiladi IsomahAdamu BabayoAbdurrahman El-Fulaty AhmadPublished in: Human vaccines & immunotherapeutics (2020)
The incidence and case-fatality rates (CFRs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the etiological agent for Coronavirus Disease 2019 (COVID-19), have been rising unabated. Even though the entire world has been implementing infection prevention and control measures, the pandemic continues to spread. It has been widely accepted that preventive vaccination strategies are the public health measures for countering this pandemic. This study critically reviews the latest scientific advancement in genomics, replication pattern, pathogenesis, and immunopathology of SARS-CoV-2 infection and how these concepts could be used in the development of vaccines. We also offer a detailed discussion on the anticipated potency, efficacy, safety, and pharmaco-economic issues that are and will be associated with candidate COVID-19 vaccines.